FB2001
Sponsors
Frontier Biotechnologies Inc., Ruijin Hospital
Conditions
COVID-19Close Contact TransmissionCovid19Mild to Moderate COVID-19
Phase 1
The Safety and Efficacy of FB2001 in Healthy Subjects and Patients With COVID-19 Infection
CompletedNCT04766931
Start: 2021-03-17End: 2022-08-12Updated: 2022-11-28
A Bridging Study of FB2001 in Healthy Subjects
CompletedNCT05197179
Start: 2021-12-29End: 2022-06-02Updated: 2022-07-06
Exploratory Study of Aerosol Inhalation of FB2001 for Post-exposure Prophylaxis of COVID-19 Close Contacts
NCT05415241
Start: 2022-06-09End: 2022-12-31Target: 60Updated: 2022-06-13
Phase 2
Evaluate the Efficacy and Safety of FB2001 in Hospitalized Patients With Moderate to Severe COVID-19 (BRIGHT Study)
NCT05445934
Start: 2022-09-14End: 2023-12-31Target: 1188Updated: 2023-01-05
Evaluate the Efficacy and Safety of FB2001 for Inhalation in Patients With Mild to Moderate COVID-19
NCT05675072
Start: 2023-01-04End: 2023-12-31Target: 1336Updated: 2023-01-09